| Category | FY | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
|
Anthrax
|
2013
|
NIAID
|
5R01AI069227-07
|
|
Surface Proteins of Bacillus anthracis
|
SCHNEEWIND, OLAF
|
UNIVERSITY OF CHICAGO
|
IL
|
$361,547
|
|
Anthrax
|
2013
|
NIGMS
|
5R01GM035370-28
|
|
Genetics of secretion in yeast
|
NOVICK, PETER
|
UNIVERSITY OF CALIFORNIA
|
CA
|
$401,683
|
|
Anthrax
|
2013
|
NIAID
|
5R01AI057472-09
|
|
Isolation of new phage enzymes to kill B. anthracis
|
FISCHETTI, VINCENT
|
ROCKEFELLER UNIVERSITY
|
NY
|
$393,179
|
|
Anthrax
|
2013
|
NIAID
|
5R01AI043197-16
|
|
Alternative approaches for NALT-based immunity to respiratory pathogens
|
BOYAKA, PROSPER
|
OHIO STATE UNIVERSITY
|
OH
|
$345,486
|
|
Anthrax
|
2013
|
NIAID
|
5R01AI090085-03
|
|
CryoEM analysis of Anthrax Toxin Pore Complexes
|
FISHER, MARK
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
KS
|
$352,500
|
|
Anthrax
|
2013
|
NIAID
|
5R21AI094564-02
|
|
Evaluation of the nasal adjuvant activity of angiotensin peptide Ang-(1-7)
|
STAATS, HERMAN
|
DUKE UNIVERSITY
|
NC
|
$234,930
|
|
Anthrax
|
2013
|
NIAID
|
1R15AI103883-01
|
|
The role of calcium-DPA in the virulence of Bacillus anthracis spores
|
ABEL-SANTOS, ERNESTO
|
UNIVERSITY OF NEVADA LAS VEGAS
|
NV
|
$398,515
|
|
Anthrax
|
2013
|
NIAID
|
5F31AI094961-03
|
|
Protective Effects of Anti-BclA Antibodies in Bacillus anthracis Infection
|
RODRIGUEZ BARRANTES, JUAN
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
AL
|
$34,094
|
|
Anthrax
|
2013
|
NIAID
|
5U01AI082086-05
|
|
Multivalent Plague, Anthrax Vaccines Using Bacteriophage T4 Display
|
RAO, VENIGALLA
|
CATHOLIC UNIVERSITY OF AMERICA
|
DC
|
$726,001
|
|
Anthrax
|
2013
|
NIAID
|
1R01AI099097-01A1
|
|
Bacillus anthracis Targets Involved in Chemokine-Mediated Antimicrobial Activity
|
HUGHES, MOLLY
|
UNIVERSITY OF VIRGINIA
|
VA
|
$371,300
|
|
Anthrax
|
2013
|
NIAID
|
5U54AI057156-10
|
6297
|
Administrative Core
|
WALKER, DAVID
|
UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
|
TX
|
$683,168
|
|
Anthrax
|
2013
|
NIGMS
|
5R01GM097357-02
|
|
Integrated Methods for Structural Elucidation of Proteins and Macromolecular Comp
|
WILLIAMS, EVAN
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$241,832
|
|
Anthrax
|
2013
|
NIAID
|
5U54AI057168-10
|
5659
|
Multiplexed ultra fast and sensitive bioagent assays- Diagnostics
|
GEDDES, CHRISTOPHER
|
UNIVERSITY OF MARYLAND BALTIMORE
|
MD
|
$247,930
|
|
Anthrax
|
2013
|
NIAID
|
1R21AI099851-01A1
|
|
Microparticle Capture-Based Analysis of Lymph Node Proteome
|
POPOV, SERGUEI
|
GEORGE MASON UNIVERSITY
|
VA
|
$184,063
|
|
Anthrax
|
2013
|
NIGMS
|
5SC1GM095475-03
|
|
Receptor disulfide allosteric regulation of anthrax toxin action
|
SUN, JIANJUN
|
UNIVERSITY OF TEXAS EL PASO
|
TX
|
$216,401
|
|
Anthrax
|
2013
|
NIAID
|
5U54AI057158-10
|
5678
|
Animal Core
|
PERLIN, DAVID
|
UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL
|
NJ
|
$642,921
|
|
Anthrax
|
2013
|
NIAID
|
5U54AI057158-10
|
5701
|
Development of new passive immunization strategies for anthrax
|
CASADEVALL, ARTURO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
NY
|
$861,684
|
|
Anthrax
|
2013
|
NIAID
|
5R21AI096314-02
|
|
Bacterial Heme Transport by non-Isd NEAT Proteins
|
MARESSO, ANTHONY
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$195,625
|
|
Anthrax
|
2013
|
NIAID
|
5U54AI057153-10
|
5860
|
Therapies of infections caused by gram-positive bacteria
|
MISSIAKAS, DOMINIQUE
|
UNIVERSITY OF CHICAGO
|
IL
|
$467,943
|
|
Anthrax
|
2013
|
NIAID
|
5U54AI057153-10
|
5867
|
Structural basis for selctive lysis of anthrax and drug-resistant S. aureus
|
FISCHETTI, VINCENT
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$273,455
|
|
Anthrax
|
2013
|
NIAID
|
5U54AI057153-10
|
5872
|
Animal Research and Immunology Core
|
MISSIAKAS, DOMINIQUE
|
UNIVERSITY OF CHICAGO
|
IL
|
$414,254
|
|
Anthrax
|
2013
|
NIAID
|
5R01AI098844-02
|
|
Final preclinical development of an immunoadhesin therapy for inhalation anthrax
|
WYCOFF, KEITH
|
PLANET BIOTECHNOLOGY, INC.
|
CA
|
$715,128
|
|
Anthrax
|
2013
|
NIAID
|
5R01AI093365-03
|
|
Immunoassay for capsular antigen for rapid diagnosis of anthrax
|
KOZEL, THOMAS
|
UNIVERSITY OF NEVADA RENO
|
NV
|
$638,260
|
|
Anthrax
|
2013
|
NIAID
|
5R01AI093397-03
|
|
cGMP manufacturing of PBI-220, a broad spectrum immunoadhesin therapeutic against
|
YU, LLOYD
|
PLANET BIOTECHNOLOGY, INC.
|
CA
|
$1,145,064
|
|
Anthrax
|
2013
|
NIAID
|
5R01AI098884-02
|
|
Development of Enabling Vector/Antigen Expression Technology for an Orally-Delive
|
SIM, B.
|
PROTEIN POTENTIAL, LLC
|
MD
|
$1,063,088
|
|
Anthrax
|
2013
|
NIAID
|
5R01AI090802-04
|
|
Optimization of Neoglycoside Antibiotics for Nosocomial Pathogens and Select Agen
|
DRUSANO, GEORGE
|
UNIVERSITY OF FLORIDA
|
FL
|
$657,363
|
|
Anthrax
|
2013
|
NIAID
|
5U19AI057266-10
|
8182
|
Human Monoclonal Antibodies
|
WILSON, PATRICK
|
UNIVERSITY OF CHICAGO
|
IL
|
$549,448
|
|
Anthrax
|
2013
|
NIAID
|
5R01AI093459-03
|
|
IMPDH-targeted antibiotics for select agents
|
HEDSTROM, LIZBETH
|
BRANDEIS UNIVERSITY
|
MA
|
$995,211
|
|
Anthrax
|
2013
|
NIAID
|
1R34AI104506-01
|
|
Phase I clinical trial of an immunoadhesin antitoxin for anthrax
|
WYCOFF, KEITH
|
PLANET BIOTECHNOLOGY, INC.
|
CA
|
$148,772
|
|
Anthrax
|
2013
|
NIAID
|
1R01AI104586-01
|
|
IND Enabling Studies for Small Molecule Anthrax Lethal Factor Inhibitors
|
JOHNSON, ALAN
|
PANTHERA BIOPHARMA, LLC
|
HI
|
$1,760,729
|
|
Anthrax
|
2013
|
NIGMS
|
2SC3GM084809-05A1
|
|
Synthesis of new classes of metal ion chelators for therapeutic applications
|
GOPALAN, ARAVAMUDAN
|
NEW MEXICO STATE UNIVERSITY LAS CRUCES
|
NM
|
$109,500
|
|
Anthrax
|
2013
|
NIAID
|
5R01AI033537-19
|
|
Virulence Gene Expression by Bacillus anthracis
|
KOEHLER, THERESA
|
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
|
TX
|
$359,683
|
|
Anthrax
|
2013
|
NIAID
|
5R01AI090685-04
|
|
Broad-spectrum Antifolates for Treatment of Drug Resistant Bacillus anthracis
|
BARROW, WILLIAM
|
OKLAHOMA STATE UNIVERSITY STILLWATER
|
OK
|
$732,571
|
|
Anthrax
|
2013
|
NIAID
|
5R44AI090719-04
|
|
Development of a Novel PolC Inhibitor as a Gram-Positive Antibiotic
|
JARVIS, THALE
|
CRESTONE, INC.
|
CO
|
$1,000,000
|
|
Anthrax
|
2013
|
NIAID
|
5R01AI097167-02
|
|
Iron Acquisition in Anthrax
|
MARESSO, ANTHONY
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$367,775
|
|
Anthrax
|
2013
|
NIAID
|
1R01AI105172-01
|
|
Conjugate Anthrax Vaccine with Dual Virulence Factor Specificity
|
GIRI, LALLAN
|
BIOLOGICS RESOURCES, LLC
|
MD
|
$890,499
|
|
Anthrax
|
2013
|
NIAID
|
5U01AI082226-05
|
|
Stimulated Innate Resistance of the Lungs to Bioterror pathogens
|
HOOK, AXEL
|
TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
|
TX
|
$423,558
|
|
Anthrax
|
2013
|
NIAID
|
5R21AI101093-02
|
|
Exposporium determinants of Bacillus anthracis
|
STEWART, GEORGE
|
UNIVERSITY OF MISSOURI-COLUMBIA
|
MO
|
$204,827
|
|
Anthrax
|
2013
|
NIAID
|
5U01AI082081-05
|
|
Broad-Spectrum Antimicrobials Targeting the D-Alanine Pathway
|
ANTHONY, KAREN
|
L2 DIAGNOSTICS, LLC
|
CT
|
$1,605,387
|
|
Anthrax
|
2013
|
NIGMS
|
5R01GM029210-35
|
|
Gating of Protein Channels in Lipid Bilayer Membranes
|
FINKELSTEIN, ALAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
NY
|
$715,082
|
|
Anthrax
|
2013
|
NIAID
|
5R01AI093493-03
|
|
A novel anti-spore nasal vaccine for protection from anthrax
|
DRIKS, ADAM
|
LOYOLA UNIVERSITY CHICAGO
|
IL
|
$624,087
|
|
Anthrax
|
2013
|
NIAID
|
2R01AI077703-05A1
|
|
Physical Principles of Bacterial Toxin Translocation across Membranes
|
KRANTZ, BRYAN
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$351,098
|
|
Anthrax
|
2013
|
NIAID
|
5R01AI093370-04
|
|
Novel multivalent vaccine for anthrax and botulinum
|
MOHAMADZADEH, MANSOUR
|
UNIVERSITY OF FLORIDA
|
FL
|
$610,583
|
|
Anthrax
|
2013
|
NIAID
|
5R21AI102223-02
|
|
Host Vascular Mechanism for Therapeutic Protection against Select Pathogens
|
CHAN, JOANNE
|
CHILDREN'S HOSPITAL CORPORATION
|
MA
|
$226,137
|
|
Anthrax
|
2013
|
NIAID
|
5R01AI095293-02
|
|
Bacillus Anthracis and Complement
|
XU, YI
|
TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
|
TX
|
$339,832
|
|
Anthrax
|
2013
|
NIAID
|
5R01AI095488-02
|
|
Peptide-Based Quorum Sensing Controlling Virulence in Bacillus anthracis
|
LEE, HYUNWOO
|
UNIVERSITY OF ILLINOIS
|
IL
|
$374,825
|
|
Anthrax
|
2013
|
NIAID
|
272200800006C-12-0-6
|
|
VACCINE AND TREATMENT EVALUATION UNITS
|
BERNSTIEN, DAVID
|
CINCINNATI CHILDRENS HOSP MED CTR
|
OH
|
$462,625
|
|
Anthrax
|
2013
|
NIAID
|
272200800005C-10-0-7
|
|
VACCINE AND EVALUTION TREATMENT UNITS
|
MULLIGAN, MARK
|
EMORY UNIVERSITY
|
GA
|
$426,364
|
|
Anthrax
|
2013
|
NIAID
|
272200800004C-10-0-2
|
|
Vaccine and Treatment Evaluation Units
|
JACKSON, LISA
|
GROUP HEALTH COOPERATIVE
|
WA
|
$744,662
|
|
Anthrax
|
2013
|
NIAID
|
272200800002C-14-0-2
|
|
Vaccine and Treatment Evaluation Units
|
KEITEL, WENDY
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$333,309
|
|
Anthrax
|
2013
|
NIAID
|
272201000035C-5-0-1
|
|
Development of Technologies to Facilitate the Use of and Response to Vaccines
|
LEMIALE, LAURENCE
|
EMERGENT PRODUCT DEVELOPMENT GAITHERSBUR
|
MD
|
$2,045,144
|
|
Anthrax
|
2013
|
NIAID
|
7R01AI093418-03
|
|
Point-of-care concentration and detection of pathogen antigens in samples
|
CANGELOSI, GERARD
|
UNIVERSITY OF WASHINGTON
|
WA
|
$502,688
|
|
Anthrax
|
2013
|
NCI
|
261200800001E-52-0-3
|
|
DCTD Computer Support
|
HEIMBROOK, DAVID
|
SAIC-FREDERICK, INC.
|
MD
|
$1,421,384
|
|
Anthrax
|
2013
|
NIAID
|
272201000036C-4-0-1
|
|
Development of Technologies to Facilitate the use and Response of Vaccines
|
GURWITH, MARC
|
PAXVAX, INC.
|
CA
|
$10,792,404
|
|
Anthrax
|
2013
|
NIAID
|
272201200026C-3-0-2
|
|
STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES
|
ANDERSON, WAYNE
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
IL
|
$2,191,313
|
|
Anthrax
|
2013
|
NIAID
|
N01AI40095-60-0-5
|
|
Task 18 (D24) Efficacy Testing of Therapeutics Against Inhalational Anthrax
|
NO PI IDENTIFIED
|
LOVELACE BIOMEDICAL & ENVIRONMENTAL RES
|
NM
|
$563,039
|
|
Anthrax
|
2013
|
OD
|
3R21AI095810-02S1
|
|
Proteomics of RNA polymerase interactomes in pathogenic bacteria
|
NUDLER, EVGENY
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$105,625
|
|
Anthrax
|
2013
|
NIAID
|
3R01AI033537-19S1
|
|
Virulence Gene Expression by Bacillus anthracis
|
KOEHLER, THERESA
|
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
|
TX
|
$66,022
|
|
Anthrax
|
2013
|
NIAID
|
272201000027C-6-0-8
|
|
Microbiology and Infectious Diseases Biological Research Resource Repository
|
STEDMAN, TIMOTHY
|
AMERICAN TYPE CULTURE COLLECTION
|
VA
|
$1,049,268
|
|
Anthrax
|
2013
|
NIAID
|
272201100028C-5-0-2
|
|
DEVELOPMENT OF NOVEL TETRACYCLINE COUNTERMEASURES FOR RESPIRATORY DISEASE
|
RADCLIFF, ANNE
|
CUBRC, INC.
|
NY
|
$3,227,357
|
|
Anthrax
|
2013
|
NIAID
|
AAI13004001-1-0-1
|
|
Development of a Non-Human Primate Model for Testing of Therapeutics for Anthrax
|
NO PI IDENTIFIED
|
NIH
|
|
$1,339,083
|
|
Anthrax
|
2013
|
NIAID
|
2R56AI070654-06
|
|
Analyzing Anthrax Toxins in Drosophilia
|
BIER, ETHAN
|
UNIVERSITY OF CALIFORNIA
|
CA
|
$364,250
|
|
Anthrax
|
2013
|
NIAID
|
5U19AI062629-10
|
7116
|
Edema Toxin Suppression of Immune Responses During Anthrax Disease
|
BALLARD, JIMMY
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
OK
|
$365,813
|
|
Anthrax
|
2013
|
NIAID
|
5U19AI062629-10
|
7117
|
Role of B. anthracis Toxins in Human Inhalation Anthrax
|
METCALF, JORDAN
|
UNIVERSITY OF OKLAHOMA
|
OK
|
$403,295
|
|
Anthrax
|
2013
|
NIAID
|
5U19AI062629-10
|
7118
|
B. anthracis Peptidoglycan as a Pro-inflammatory Agent in Anthrax Pathogenesis
|
COGGESHALL, KENNETH
|
OKLAHOMA MEDICAL RESEARCH FOUNDATION
|
OK
|
$385,765
|
|
Anthrax
|
2013
|
NIAID
|
5U19AI062629-10
|
7119
|
Characterization of Protective Humoral Anthrax Immunity
|
JAMES, JUDITH
|
OKLAHOMA MEDICAL RESEARCH FOUNDATION
|
OK
|
$477,330
|
|
Anthrax
|
2013
|
NIAID
|
5U19AI062629-10
|
7120
|
Reverse Genomics of Anti-Protective Antigen Responses
|
HARLEY, JOHN
|
OKLAHOMA MEDICAL RESEARCH FOUNDATION
|
OK
|
$78,767
|
|
Anthrax
|
2013
|
NIAID
|
5U19AI062629-10
|
7121
|
Translation of immunologic technologies from basic research into pre-clinical non
|
KUROSAWA, SHINICHIRO
|
BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
|
MA
|
$401,460
|
|
Anthrax
|
2013
|
NIAID
|
5U19AI062629-10
|
7123
|
Educational Component
|
FARRIS, A. DARISE
|
OKLAHOMA MEDICAL RESEARCH FOUNDATION
|
OK
|
$55,998
|
|
Anthrax
|
2013
|
NIAID
|
5U19AI062629-10
|
7124
|
Administration Core
|
COGGESHALL, KENNETH
|
OKLAHOMA MEDICAL RESEARCH FOUNDATION
|
OK
|
$162,877
|
|
Anthrax
|
2013
|
NIAID
|
5U19AI062629-10
|
7125
|
Pilot Project Program
|
BALLARD, JIMMY
|
OKLAHOMA MEDICAL RESEARCH FOUNDATION
|
OK
|
$228,970
|
|
Anthrax
|
2013
|
NIAID
|
5U19AI062629-10
|
7126
|
Scientific Core: Flow Cytometry and Sorting Core Facility
|
KINCADE, PAUL
|
OKLAHOMA MEDICAL RESEARCH FOUNDATION
|
OK
|
$68,442
|
|
Anthrax
|
2013
|
NIAID
|
5U19AI062629-10
|
7127
|
Scientific Core: Bacillus anthracis Anthrax Toxin Core
|
BALLARD, JIMMY
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
OK
|
$74,745
|
|
Anthrax
|
2013
|
NIAID
|
272201000013I-0-27200004-1
|
|
Task C19: Efficacy of amoxicillin in NHP model of anthrax
|
MIRSALIS, JON
|
PUBLIC HEALTH ENGLAND
|
UK
|
$2,156,042
|
|
Anthrax
|
2013
|
NICHD
|
1ZIAHD000072-10
|
|
Biophysics of Large Membrane Channels
|
BEZRUKOV, SERGEY
|
NIH
|
|
$950,370
|
|
Anthrax
|
2013
|
NIDDK
|
1ZIADK059701-40
|
|
Reactions And Immunochemistry Of Carbohydrates
|
KOVAC, PAVOL
|
NIH
|
|
$802,050
|
|
Anthrax
|
2013
|
NIDDK
|
1ZICDK070011-07
|
|
Production , purification and preparation of various candidiate vaccines
|
SHILOACH, JOSEPH
|
NIH
|
|
$285,933
|
|
Anthrax
|
2013
|
NIAID
|
272201000003I-1-27200002-1
|
|
Task B1: Validation of the MSD Protective Antigen(PA)-ECL Assay
|
SAIA, TERI
|
BATTELLE CENTERS/PUB HLTH RES & EVALUATN
|
OH
|
$193,187
|
|
Anthrax
|
2013
|
NIAID
|
272201000003I-0-27200010-1
|
|
Task B02: Comparison of anthrax antitoxins in a challenge study
|
SAIA, TERI
|
BATTELLE CENTERS/PUB HLTH RES & EVALUATN
|
OH
|
$1,388,525
|
|
Anthrax
|
2013
|
NIAID
|
1ZIAAI000929-11
|
|
Vaccines and Therapeutics for Anthrax
|
LEPPLA, STEPHEN
|
NIH
|
|
$847,612
|
|
Anthrax
|
2013
|
NIAID
|
1ZIAAI000936-10
|
|
Pathogenesis, Treatment and Prevention of Emerging Infectious Diseases
|
LANE, CLIFFORD
|
NIH
|
|
$191,279
|
|
Anthrax
|
2013
|
NIAID
|
1ZIAAI000984-07
|
|
Influenza and Emerging Infectious Diseases
|
DAVEY, RICHARD
|
NIH
|
|
$2,009,368
|
|
Anthrax
|
2013
|
NIAID
|
1ZIAAI001030-06
|
|
Molecular Genetics and Pathogenesis of Anthrax
|
LEPPLA, STEPHEN
|
NIH
|
|
$484,350
|
|
Anthrax
|
2013
|
NIAID
|
1ZIAAI001031-06
|
|
Structure and Function of Virulence Factors of Bacillus anthracis
|
LEPPLA, STEPHEN
|
NIH
|
|
$605,437
|
|
Anthrax
|
2013
|
NIAID
|
1ZIAAI001032-06
|
|
Pathophysiological Actions of Anthrax Virulence Determinants
|
LEPPLA, STEPHEN
|
NIH
|
|
$484,350
|
|
Anthrax
|
2013
|
NIAID
|
272200900033C-5-0-1
|
|
Novel adjuvants acting through TLR2, TLR5 and TLR7 receptors
|
DAVID, SUNIL
|
UNIVERSITY OF KANSAS LAWRENCE
|
KS
|
$1,344,542
|
|
Anthrax
|
2013
|
NIAID
|
272201300029C-0-0-1
|
|
Development of an Adjuvant with Vaccines for Anthrax, and West Nile Virus (WNV)
|
KOONTZ, CASEY
|
SCIENCE APPLICATIONS INTE
|
VA
|
$2,244,621
|
|
Anthrax
|
2013
|
NIAID
|
272201200003I-0-27200002-1
|
|
Task X2: Evaluation of Anthrax Vaccines (AVA)
|
KNETEMAN, NORMAN
|
BATTELLE CENTERS/PUB HLTH RES & EVALUATN
|
OH
|
$1,520,428
|
|
Anthrax
|
2013
|
NIAID
|
272201200003I-0-27200004-1
|
|
Task X 4: Assessment of Simple Adjuvants to Enhance Anthrax Vaccines
|
KNETEMAN, NORMAN
|
BATTELLE CENTERS/PUB HLTH RES & EVALUATN
|
OH
|
$1,404,153
|
|
